ACHN Key Stats
- Nasdaq stocks posting largest percentage decreases May 22
- Achillion Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, Ma... May 21
- 7 Biotechnology Stocks to Sell Now Investor Place May 15
- The Young And Restless Retirement Portfolio: Stay The Course Seeking Alpha May 15
- Achillion Names Dr. David Apelian CMO Benzinga May 15
- Achillion Appoints Dr. David Apelian as Chief Medical Officer and Expands Clinic... May 15
- Achillion: Down But Not Out And Progress Being Made May 10
- Achillion to Present at Three Upcoming Investor Conferences GlobeNewswire May 9
- 7 Biotechnology Stocks to Sell Now Investor Place May 8
- ACHILLION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 7
ACHN Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Achillion Pharmaceuticals is up 3.55% over the last year vs S&P 500 Total Return up 27.77%, Acorda Therapeutics up 44.17%, and Discovery Laboratories down 38.46%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for ACHN
Pro Report PDF for ACHN
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ACHN Pro Report PDF
Pro Strategies Featuring ACHN
Did Achillion Pharmaceuticals make it into our Pro Portfolio Strategies?